A Long-Term, Open-Label, Study on Schizophrenia
A Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients With DSM-IV-TR Schizophrenia
Sponsor: Eli Lilly and Company
Terminated
The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.
Other terminated trials from Eli Lilly and Company
This PHASE2/PHASE3 trial investigates Schizophrenia and is currently terminated or withdrawn. Eli Lilly and Company leads this study, which shows 13 recorded versions since 2010 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
13 versions recorded-
Oct 2025 — Present [monthly]
Terminated PHASE2/PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Terminated PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
▶ Show 8 earlier versions
-
Dec 2021 — Apr 2022 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2_PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE2_PHASE3
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2_PHASE3
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE2_PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2_PHASE3
First recorded
Jun 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .